Literature DB >> 21159773

How small changes led to big profits for insulin manufacturers.

Deborah Cohen1, Philip Carter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21159773     DOI： 10.1136/bmj.c7139

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Choice of long-acting insulin therapy for type 2 diabetes: how can treatment for older people be optimized?

Authors:  Andrew J Krentz; Alan J Sinclair
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 2.  Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.

Authors:  Dorairaj Prabhakaran; Shuchi Anand; David Watkins; Thomas Gaziano; Yangfeng Wu; Jean Claude Mbanya; Rachel Nugent
Journal:  Lancet       Date:  2017-11-03       Impact factor: 79.321

3.  Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin.

Authors:  Sarah E Holden; Chris D Poole; Christopher Ll Morgan; Craig J Currie
Journal:  BMJ Open       Date:  2011-01-01       Impact factor: 2.692

Review 4.  Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues.

Authors:  Allan Vaag; Søren S Lund; Sørens Lund
Journal:  Eur J Endocrinol       Date:  2011-09-19       Impact factor: 6.664
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.